Latest News on Ketamine Therapy for Mental Health

The American Society of Anesthesiologists issued fresh recommendations in February 2025, stressing that ketamine treatments for psychiatric conditions must be overseen by qualified medical professionals in adequately equipped clinical environments. These guidelines emerged partly in response to safety incidents, including actor Matthew Perry’s widely publicized death.

Medical experts highlighted that improper ketamine administration can trigger dangerous complications such as elevated blood pressure, breathing difficulties that may progress to respiratory failure, heart problems, and seizures. The professional organization specifically raised red flags about home-based ketamine programs and unregulated treatment centers that may not have essential monitoring technology or emergency medical staff on hand.

Researchers at McLean Hospital and Mass General Brigham conducted a study involving 153 people with depression that hadn’t improved with other medications, comparing traditional IV ketamine against the FDA-cleared nasal spray form called esketamine. While both approaches produced positive results, the intravenous route appeared to work somewhat more quickly, with patients showing symptom improvement right after their initial session. In contrast, the nasal spray demonstrated clear benefits following the second administration.

Scientists at Vanderbilt University published findings in Science in November 2025 showing they may have discovered how to prolong ketamine’s mood-lifting effects from roughly one week to potentially two months after a single treatmentby manipulating certain biological mechanisms. This development could significantly reduce infusion frequency and minimize potential risks from repeated exposure.

New Research Studies Shaping Future of Ketamine Therapy

Emerging research is rapidly transforming our understanding of ketamine therapy, moving beyond simply documenting its effectiveness toward optimizing how it works and expanding its clinical applications. Recent studies continue to influence how ketamine is used:

• Prolonging Therapeutic Benefits: Researchers at Vanderbilt University have identified ways to manipulate specific molecular signaling pathways that could extend ketamine’s mood-improving effects from approximately seven days to as long as two months after a single treatment session, potentially reducing the frequency with which patients need to receive the medication.
• Combining with Talk Therapy: Investigations reveal that ketamine opens a brief period of increased brain adaptability and mental flexibility that can be harnessed through psychotherapy for greater impact, with evidence showing that adding cognitive behavioral therapy substantially prolonged ketamine’s positive effects in people with hard-to-treat depression, allowing those who responded well to stay in remission for as long as eight weeks after their infusions ended.
• Alternative Administration Routes: Researchers are testing under-the-tongue ketamine preparations that have successfully completed second-phase trials and are advancing into advanced development, potentially providing a more accessible option than IV infusions.
• Multimodal Treatment Protocols: Scientists are examining ketamine paired with electroconvulsive therapy, diverse therapeutic modalities such as music therapy and virtual reality experiences, transcranial magnetic stimulation, and body-centered trauma approaches like yoga for treating everything from depression and PTSD to persistent pain conditions.
• Addiction Treatment Research: Clinical teams are evaluating ketamine-supported therapy for methamphetamine addiction in people living with HIV, while nine completed randomized controlled studies have examined ketamine’s potential for addressing cocaine, alcohol, opioid, and tobacco dependence.
• Understanding Biological Pathways: Investigators are studying biological mechanisms at the gene expression level, including DNA methylation patterns and changes in how genetic material is packaged, that help explain ketamine’s quick-acting properties, while also testing different dose levels, including lower psycholytic amounts that shift consciousness subtly without causing complete dissociation.